HGH 191AA Somatropin 15IU Review

Recombinant human growth hormone (rhGH), catalogued under the 191-amino-acid sequence designation "191AA somatropin," is one of the most studied polypeptide hormones in endocrinology and metabolic biology. Its 30-year clinical history as a pharmaceutical (marketed as Genotropin, Norditropin, Humatrope, and others) has generated an exceptionally detailed body of mechanistic and pharmacokinetic literature, which makes it an unusually well-characterised reference compound for laboratory researchers investigating GH-axis biology, anabolic signalling, lipolysis, and tissue remodelling.

The research-peptide form reviewed here, Apollo Peptide Sciences' HGH 191AA Somatropin 15IU, presents this polypeptide in lyophilised, single-vial format at a nominal activity of 15 International Units. This review examines the compound's chemistry, receptor pharmacology, downstream signalling, available peer-reviewed data, pharmacokinetics, purity considerations, and how it sits within the broader landscape of GH-axis research tools, including secretagogues and IGF-1 analogs.

Editor's Verdict

For researchers building assay panels around the somatotropic axis, having a well-characterised, high-purity somatropin standard is a prerequisite. The pharmaceutical literature on rhGH is exceptionally mature, with mechanistic data from over four decades of clinical use and pre-clinical research, including the canonical GH receptor (GHR) dimerisation studies of Cunningham and colleagues ^[1], the downstream JAK2-STAT5 signalling characterisation by Argetsinger et al. ^[2], and the definitive IGF-1 axis work from the Laron and Rosenfeld laboratories.

What distinguishes 191AA somatropin from 192AA somatropin (methionyl-HGH) is the absence of a leading methionine residue. The methionyl form, produced in early bacterial expression systems, carries a slightly higher immunogenic risk in vivo and performs differently in some binding assays. ^[3] For modern receptor-binding and cell-signalling research, the 191AA sequence is the correct form to use.

At $40.00 for 15IU, Apollo Peptide Sciences' offering sits at an accessible price point. Researchers should budget additional time and cost for independent CoA verification; this review addresses what to look for in detail in the Purity section below.

Specifications

The 15IU designation maps to the World Health Organisation International Standard for somatropin (WHO IS 98/574), where one IU corresponds to approximately 0.333 mg (i.e., 3 IU per mg) of the lyophilised protein standard. This conversion is reproduced in multiple pharmacopoeial references and should be used when converting vial activity to mass-based dosing in research protocols. ^[4]

What It Is: Chemistry, Origin, and Sequence Detail

The 191-Amino-Acid Sequence

Human growth hormone is a single-chain, non-glycosylated polypeptide of 191 amino acids, synthesised and secreted by somatotroph cells in the anterior pituitary. The mature secreted form has a molecular weight of approximately 22,124 Da and contains two intramolecular disulfide bridges: one between Cys53 and Cys165, and a smaller loop between Cys182 and Cys189. ^[5] These disulfide bonds are critical for the three-dimensional fold of the molecule and for GHR binding; any oxidation or incorrect pairing during recombinant production substantially reduces biological activity.

The primary sequence begins with Phe-Pro-Thr at the N-terminus and ends with Phe at position 191. The sequence encompasses four alpha-helices (helix 1, residues 9-34; helix 2, residues 72-92; helix 3, residues 106-128; helix 4, residues 155-183) that form the canonical four-helix bundle characteristic of the cytokine superfamily. ^[5] The two receptor-binding sites (Site 1 and Site 2) are topologically distinct on this bundle and bind sequentially to two GHR extracellular domain monomers to form the active hormone-receptor complex.

The 191AA vs 192AA Distinction

The earliest recombinant somatropin products, produced via bacterial expression of a direct methionine-initiating construct, generated a 192-amino-acid protein (methionyl-HGH, or met-GH) carrying an additional N-terminal methionine residue. Somatrem (Protropin, Genentech) was the first commercial product based on this sequence. Subsequent process development achieved cleavage of the initiating methionine through optimised E. coli signal-peptide processing or through direct secretion from alternative expression vectors, yielding the 191AA form identical to the native pituitary hormone. ^[3] Comparative binding studies demonstrate that met-GH has approximately 3 percent lower affinity for GHR Site 1 binding and exhibits higher immunogenicity in subjects with GH deficiency treated long-term. ^[3] For research applications in which native receptor binding kinetics are a study endpoint, the 191AA form is the appropriate choice.

Recombinant Production Methods

Modern research-grade and pharmaceutical-grade somatropin is produced in one of two expression systems. The E. coli system (used by Genentech, Novo Nordisk, and most generic manufacturers) expresses the protein as inclusion bodies, which are then solubilised, refolded under controlled redox conditions to achieve correct disulfide pairing, and purified by multi-step column chromatography. The Chinese hamster ovary (CHO) cell system expresses and secretes properly folded protein directly, with a typically lower aggregation burden but higher production cost. Research-peptide vendors rarely disclose their expression system, so researchers should look for HPLC-SEC aggregate data on the CoA as a proxy for fold quality. Aggregate content above 5 percent by HPLC-SEC area is associated with reduced bioactivity and potential in vivo immunogenic artefacts in rodent models. ^[6]

Isoform Heterogeneity

Native pituitary GH exists as a mixture of isoforms, of which the 22 kDa monomer (the 191AA form described here) accounts for approximately 85-90 percent of circulating GH in healthy adults. ^[7] A 20 kDa isoform (lacking amino acids 32-46, arising from alternative splicing of exon 3) accounts for most of the remainder, with small amounts of dimers, oligomers, and post-translationally modified species. Recombinant 191AA somatropin is intentionally a single-isoform product; the 20 kDa isoform is not present unless the expression construct is designed to include it. This isoform homogeneity is an advantage in receptor-binding research because it eliminates confounding from heterogeneous binding kinetics, but researchers should be aware that results may not fully recapitulate effects of whole pituitary extract.

Mechanism of Action: Receptor Binding, Downstream Signalling, Tissue Distribution

GHR Receptor Binding and Sequential Dimerisation

The canonical model of GH signalling was substantially clarified by Cunningham et al. in 1991, who used X-ray crystallography to resolve the 1:2 stoichiometry of the GH:GHR complex. ^[1] GH binds a first GHR extracellular domain (ECD) monomer via its high-affinity Site 1 (located on helix 1 and helix 4, with contributions from loop regions), producing a 1:1 binary complex. This binary complex then recruits a second GHR ECD via the lower-affinity Site 2 (located primarily on helix 3), generating the active 1:2 ternary complex that drives receptor dimerisation and intracellular signal transduction. ^[1]

The sequential, ordered binding mechanism has a critical pharmacological implication: at very high concentrations, GH can occupy Site 2 of the first receptor before recruiting the second, sterically preventing dimerisation and actually antagonising signalling. This "bell-shaped" dose-response phenomenon, observed in cell-based assays, means that simply increasing GH concentration in a well does not monotonically increase downstream signalling. Researchers designing concentration-response experiments should map the full concentration range (typically 0.001 nM to 100 nM) to characterise this inversion point, which typically occurs above 10-50 nM for 22 kDa somatropin. ^[8]

JAK2-STAT5 Signalling Axis

The GHR is a member of the class 1 cytokine receptor family and lacks intrinsic tyrosine kinase activity. Instead, each GHR intracellular domain constitutively associates with Janus kinase 2 (JAK2) via its Box1/Box2 proline-rich motifs. GH-induced dimerisation brings the two JAK2 molecules into proximity, enabling transphosphorylation and activation. ^[2] Activated JAK2 phosphorylates multiple tyrosine residues on the GHR intracellular tail, creating docking sites for STAT5a and STAT5b SH2 domains. STAT5 molecules are then phosphorylated at Tyr694 (STAT5a) or Tyr699 (STAT5b), dimerize, and translocate to the nucleus to drive transcription of GH-responsive genes, most notably IGF-1, GH receptor itself, and various serine protease inhibitors. ^[2]

STAT5b is the predominant isoform mediating hepatic IGF-1 transcription, with STAT5b knockout mice showing severe GH resistance and dwarf phenotypes despite normal or elevated circulating GH. ^[9] This distinction is relevant for researchers studying liver-specific responses in hepatocyte cell lines: STAT5b expression levels should be confirmed and matched across experimental conditions.

Parallel signalling pathways activated downstream of GHR dimerisation include the RAS-ERK (mitogen-activated protein kinase) cascade, which mediates proliferative responses in several cell types, and the PI3K-AKT pathway, which is primarily responsible for the anti-apoptotic and metabolic insulin-sensitising effects observed in muscle and adipose tissue at physiological GH concentrations. ^[10] The PI3K pathway also intersects with IRS-1 signalling, providing a mechanistic bridge between direct GH effects and the indirect effects mediated through local IGF-1 production.

IGF-1 Axis and Indirect Effects

The majority of GH's anabolic and growth-promoting effects in vivo are mediated indirectly through stimulation of IGF-1 synthesis, primarily in the liver (endocrine IGF-1) but also locally in muscle, bone, kidney, and cartilage (paracrine/autocrine IGF-1). ^[11] Hepatic IGF-1 synthesis is driven by the STAT5b pathway described above; GH-responsive elements (GHREs) in the IGF-1 gene promoter and first intron are occupied by phosphorylated STAT5b dimers within 30 minutes of GH stimulation in isolated hepatocyte preparations. ^[9]

Systemic IGF-1 circulates largely bound to IGF-binding protein 3 (IGFBP-3) and the acid-labile subunit (ALS) in a ternary complex with a half-life of approximately 12-15 hours, which buffers the pulsatile nature of GH secretion and sustains tissue exposure. This means that in rodent in vivo studies, the anabolic readout (lean mass accrual, tibial growth plate width, muscle fibre cross-sectional area) reflects integrated IGF-1 exposure over days to weeks, while acute JAK2-STAT5 phosphorylation occurs within minutes to hours of rhGH injection. Researchers must design time-course experiments appropriately for which outcome they are measuring.

Lipolytic Actions in Adipose Tissue

GH exerts direct lipolytic effects in adipocytes that are partially independent of IGF-1. GHR is expressed on white and brown adipocytes; receptor activation stimulates hormone-sensitive lipase (HSL) phosphorylation and triglyceride hydrolysis, raising circulating non-esterified fatty acids (NEFAs). ^[12] At the same time, GH antagonises insulin action in adipocytes by reducing GLUT4 translocation, contributing to the characteristic "anti-insulinic" metabolic phenotype seen at pharmacological GH exposures. The balance between the lipolytic (beneficial for body composition research) and insulin-antagonising (potentially confounding for metabolic research) effects is concentration-dependent and should be accounted for in experimental designs where insulin sensitivity is an outcome variable.

Tissue Distribution of GHR Expression

GHR is expressed most abundantly in the liver, which is responsible for approximately 50 percent of circulating IGF-1 production. Significant expression also occurs in skeletal muscle, adipose tissue, kidney, cartilage, bone, heart, and brain. ^[7] In rodent studies, muscle and liver GHR expression can be regulated by nutritional status, with caloric restriction reducing hepatic GHR density and blunting the IGF-1 response to exogenous GH. Researchers using fasting protocols or caloric restriction paradigms in GH studies should include GHR and ALS measurements to interpret variable IGF-1 responses.

What the Research Says: Peer-Reviewed Evidence

Study 1: Savine and Sonksen (2000), Systematic Review of GH in Normal Subjects

Savine and Sonksen published a systematic review of rhGH administration studies in healthy adults, covering 18 placebo-controlled randomised trials from 1990-2000. ^[13] The pooled analysis found that rhGH administration increased lean body mass by a mean of 2.1 kg and reduced fat mass by 2.4 kg over 12-24-week study periods, without significant net change in body weight. Grip strength showed no consistent improvement despite the lean mass gain, a finding the authors attributed to the time required for neural adaptation to new contractile protein. Adverse effects including oedema, arthralgia, and carpal tunnel syndrome were dose-dependent and resolved on discontinuation. This review is frequently cited in GH-axis research as the benchmark for separating compositional from functional endpoints. For laboratory researchers, the implication is that body composition and strength readouts are dissociable in the short term and should be measured independently.

The study population was healthy adults without pituitary pathology, which limits extrapolation to disease models but establishes the clean pharmacodynamic signal obtainable with the 22 kDa isoform. The dose range reviewed (1-6 IU/day in human equivalents) is translated to rodent research as approximately 0.05-0.3 mg/kg/day using standard allometric scaling, providing a reference range for in vivo rodent protocol design. Limitations include heterogeneity of dosing regimens across included studies and the absence of standardised IGF-1 monitoring, making it difficult to define the dose-IGF-1-response relationship across studies.

Study 2: Johannsson et al. (1997), GH and Visceral Adiposity

Johannsson and colleagues conducted a 12-month double-blind, placebo-controlled RCT in abdominally obese men, administering rhGH (starting at 0.53 mg/day, titrated to IGF-1 response) or placebo. ^[12] The primary finding was a 17 percent reduction in visceral adipose tissue area (measured by CT scan) in the treatment group versus a 7 percent increase in placebo, alongside a significant increase in lean mass and modest improvement in insulin sensitivity at 12 months (after the initial insulin-antagonising phase seen in the first 3-6 months). HDL cholesterol increased significantly in the GH group.

This study is methodologically significant for two reasons. First, it used CT-quantified visceral fat, the most reliable readout of intra-abdominal adiposity, rather than DEXA or skinfold estimates. Second, it demonstrated that the initial insulin resistance seen with GH treatment (weeks 4-12) is transient in vivo and is succeeded by improvement in glucose metabolism, likely due to the lipolytic reduction in ectopic lipid deposition. For cell culture researchers designing metabolic assays, this temporal biphasic pattern should be modelled appropriately; short-term (24-48 hour) GH treatment in hepatocytes or myocytes may produce different insulin signalling results than chronic (7+ day) treatment.

The study was conducted in male subjects only, limiting generalisability. The dose titration approach makes it difficult to assign specific dose-response relationships to the observed outcomes.

Study 3: Corpas et al. (1993), GH in Aging Rodent Models

Corpas, Harman, and Blackman reviewed the experimental literature on GH administration in aging rodent models, summarising data from Sprague-Dawley and Fischer 344 rats. ^[14] In multiple studies, aged male rats receiving subcutaneous rhGH (0.1-0.2 mg/kg/day for 4-12 weeks) showed significant increases in tibial growth plate width, muscle mass (gastrocnemius wet weight), and hepatic IGF-1 mRNA expression relative to saline-injected controls. Bone mineral density showed modest improvement, with the most pronounced effects in the distal femur metaphysis.

For researchers designing rodent longevity or sarcopenia models, this review provides the foundational dose references. The 0.1-0.2 mg/kg/day range in rodents is the most commonly reproduced effective range in the subsequent two decades of rodent GH literature. The review also highlights a critical limitation of rodent models: IGF-1 responses to exogenous GH are substantially larger in young animals and attenuate with age, which is relevant when designing aging-model studies where diminished response should be anticipated in the control arm design.

Study 4: Ariyasu et al. (2001), GH Secretagogue vs Direct GH Comparison

Ariyasu and colleagues compared the GH-axis response to ghrelin (an endogenous GH secretagogue) with that of direct exogenous GH administration in rats, providing a mechanistic comparison relevant to researchers choosing between secretagogues (such as GHRP-6, ipamorelin, or MK-677) and direct somatropin. ^[15] At matched doses designed to produce similar peak GH concentrations, direct GH produced a more acute and higher-amplitude GH peak with faster IGF-1 induction, while ghrelin produced a lower-amplitude but more physiologically pulsatile pattern that was associated with higher GH receptor upregulation after 4 weeks of treatment.

This study carries significant implications for assay design. If a researcher's endpoint is acute JAK2-STAT5 phosphorylation amplitude (e.g., in a hepatocyte stimulation assay), direct somatropin produces the cleaner, higher-amplitude signal. If the endpoint is chronic adaptation (GHR density, IGFBP-3 levels, receptor sensitivity), the secretagogue pattern may produce more physiologically relevant results. The Ariyasu data are commonly cited when researchers justify compound selection in GH-axis study design sections. Limitations include the use of a single rodent species and only one timepoint for receptor density measurement.

Study 5: Giustina and Veldhuis (1998), GH Secretion Physiology

Giustina and Veldhuis published a landmark review of GH secretion regulation, covering pulse frequency, amplitude, and neuroendocrine regulation across species, ages, and physiological states. ^[7] While not an interventional study, this review is required reading for researchers designing in vivo GH studies because it establishes the pulsatile baseline against which exogenous administration is superimposed. In rats, GH secretion occurs in high-amplitude pulses every 3-4 hours; continuous subcutaneous infusion suppresses endogenous GH pulses (via GHSR desensitisation and somatostatin feedback) while maintaining steady-state IGF-1. Pulse-dosed injections more closely mimic physiological patterns but produce variable IGF-1 responses depending on inter-dose interval.

For researchers using the Apollo Peptide Sciences HGH 191AA product in rodent studies, this pharmacological context argues for pulse-dosed subcutaneous injection rather than osmotic minipump infusion when the endpoint is IGF-1-dependent tissue growth, and for infusion when the endpoint is receptor signalling studies where controlled and constant receptor occupancy is required.

Pharmacokinetics

Absorption and Distribution

After subcutaneous administration, rhGH is absorbed from the depot via lymphatic uptake and direct capillary diffusion. The absorption phase follows first-order kinetics with a rate constant that varies by injection site; abdominal and deltoid sites show faster absorption than thigh in human PK studies. ^[16] The volume of distribution at approximately 0.07 L/kg reflects primarily extracellular fluid distribution, consistent with the peptide's size and its inability to cross lipid membranes. Receptor-mediated uptake into GHR-expressing tissues (liver, muscle) contributes to tissue distribution and accounts for a portion of the apparent non-renal clearance.

Approximately 45 percent of circulating GH is bound to growth hormone binding protein (GHBP), a truncated soluble form of the GHR extracellular domain generated by proteolytic cleavage in humans (and by alternative splicing in rodents). ^[16] GHBP binding prolongs the circulating half-life of bound GH but also reduces free GH availability for receptor engagement at target tissues. This buffer effect is dose-dependent: at pharmacological GH concentrations, GHBP becomes saturated and free GH fraction rises disproportionately.

Metabolism and Elimination

GH is cleared primarily by the liver and kidney. Hepatic clearance involves receptor-mediated endocytosis via GHR, with lysosomal degradation of the hormone-receptor complex. Renal clearance involves glomerular filtration of the unbound fraction (22 kDa is below the practical renal sieving cutoff of approximately 60 kDa for intact spherical proteins, though the non-spherical shape of GH allows partial filtration) followed by tubular reabsorption and proteolysis. ^[16] Total clearance of approximately 116-174 mL/h/kg corresponds to a systemic half-life of 15-30 minutes after intravenous administration and the longer subcutaneous apparent half-life reflects the absorption-rate-limited ("flip-flop") kinetics rather than true elimination kinetics.

Rodent vs Human PK Scaling

In rats, GH pharmacokinetics are substantially faster due to higher metabolic rate. The intravenous half-life of rhGH in rats is approximately 6-10 minutes, and the subcutaneous apparent half-life is approximately 30-60 minutes at doses of 0.1-0.5 mg/kg. ^[14] Researchers scaling from human PK literature should apply allometric scaling (exponent 0.75 for clearance) rather than simple linear conversion. The practical implication is that once-daily subcutaneous dosing protocols used in human pharmacology research produce near-continuous exposure in humans but distinctly pulsatile exposure in rats; to achieve continuous rodent exposure, osmotic minipump delivery or multiple daily injections are required.

Purity and Verification

Aggregate Content and Bioactivity

The most common purity problem with research-grade lyophilised rhGH is protein aggregation. Aggregates form during three stages of the product lifecycle: during the refolding step of E. coli-derived production, during lyophilisation if freeze-drying cycles are not optimised, and during reconstitution if inappropriate diluents or temperatures are used. ^[6] Aggregated rhGH retains its apparent molecular weight on standard SDS-PAGE under reducing conditions (because aggregation is often non-covalent) but shows elevated high-molecular-weight peaks on native or non-reducing HPLC-SEC. Importantly, aggregated forms have reduced GHR-binding affinity and in vitro bioactivity, meaning that a product showing 98 percent purity on SDS-PAGE may have only 60-70 percent of the expected receptor-binding activity if aggregates are present.

The Nb2 lymphocyte proliferation bioassay (using Nb2-11 rat lymphoma cells, which proliferate in response to prolactin and GH due to their GHR/prolactin receptor expression) is the classical bioassay for somatropin activity. ^[4] This assay detects both receptor-binding potency and signalling competence, making it a more comprehensive assessment of biological activity than binding studies alone. A reputable CoA should ideally report specific activity in IU/mg against the WHO IS 98/574 standard, with a target of 2.6-3.4 IU/mg for high-quality material (centred on the nominal 3 IU/mg conversion).

Independent Verification Approaches

Researchers who need to confirm the identity and purity of the received material before use in publications should consider the following sequence. First, reconstitute a small aliquot in bacteriostatic water at 0.5 mg/mL and inject a 10 microlitre sample onto a size-exclusion column calibrated with protein standards; the monomer peak should elute at approximately 22 kDa with no high-molecular-weight leading peak above 2-3 percent of total area. Second, submit an aliquot for electrospray ionisation mass spectrometry (ESI-MS) at a contract analytical laboratory, confirming the 22,124 Da monomer mass and absence of significant peaks at 22,247 Da (which would indicate the methionyl-192AA form). Third, run a Western blot using an anti-GH antibody (e.g., Millipore anti-human GH clone GH1) to confirm the 22 kDa band and absence of truncated degradation products.

For endotoxin, a recombinant factor C (rFC) fluorescent endotoxin assay can be performed in-house if the appropriate kit is available; the LAL gel-clot method requires a licensed laboratory in most jurisdictions. Any endotoxin reading above 1 EU/mg in material intended for in vivo rodent studies should prompt reconsideration of the vial before use, as GH-research endpoints including body weight, food intake, and IGF-1 levels can all be confounded by endotoxin-induced acute phase responses. ^[6]

Dosage and Reconstitution

Reconstitution

Lyophilised somatropin should be reconstituted by adding bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection slowly down the inside wall of the vial, avoiding direct stream onto the lyophilised cake. Swirl gently; do not vortex. Allow 30-60 seconds for complete dissolution; some formulations may require up to 5 minutes at 4 degrees Celsius on a rocking platform. For detailed step-by-step guidance, see our reconstitution guide.

The choice of diluent affects stability. Bacteriostatic water (0.9% benzyl alcohol) is the preferred diluent for multi-use vials because benzyl alcohol inhibits microbial growth over the 14-day post-reconstitution window. If bacteriostatic water is unavailable, sterile water for injection is acceptable for single-use aliquots only; reconstituted rhGH in sterile water should be used within 24 hours or aliquotted and refrozen at -20 degrees Celsius (one freeze-thaw cycle maximum is generally tolerated without significant activity loss, though each cycle degrades protein to some degree). ^[6]

Calculating Research Concentrations

For in vitro cell-based assays, rhGH is typically used at concentrations of 10-1000 ng/mL (approximately 0.45-45 nM), spanning the physiological-to-pharmacological range. Preparing a stock solution of 1 mg/mL (1000 micrograms/mL) allows convenient dilution into assay medium.

Worked Example 1 (Stock Preparation): The 15IU vial contains approximately 5 mg of rhGH (15 IU divided by 3 IU/mg). Adding 5 mL of bacteriostatic water yields a 1 mg/mL (1000 micrograms/mL) stock solution. This stock can then be serially diluted to working concentrations. Adding 10 microlitre of this stock to 990 microlitre of culture medium yields a 10 micrograms/mL (10,000 ng/mL) working solution; a further 1:100 dilution in medium produces 100 ng/mL (4.5 nM), which is within the standard in vitro GHR activation range.

Worked Example 2 (Rodent In Vivo Dose): For a published protocol using 0.1 mg/kg/day in 250 g Sprague-Dawley rats, the dose per animal is 0.025 mg (25 micrograms). Using the 1 mg/mL stock above, each animal receives 25 microlitre of the stock solution subcutaneously. For a 10-animal group receiving twice-daily injections, each injection dose is 12.5 micrograms per injection (12.5 microlitre of the stock), totalling 250 microlitre per day across the group. The 5 mg vial provides enough material for approximately 200 rat-days at this dose, or 20 rat-days at 0.5 mg/kg/day.

Worked Example 3 (Allometric Scaling from Human Literature): A human pharmacology study uses 2 IU/day (approximately 0.67 mg/day for an 80 kg subject, or approximately 8.3 micrograms/kg/day). Allometric scaling to rat using the body surface area method (factor approximately 6.2 for rat-to-human conversion) yields an equivalent rat dose of approximately 51 micrograms/kg/day. This falls within the 0.05-0.1 mg/kg/day range commonly used in rodent efficacy studies, validating the allometric approach. For a detailed calculator and additional worked examples, see our dosage calculation guide.

Side Effects and Safety Profile

GH Excess Phenotype in Animal Models

The adverse effect profile of GH excess is well-characterised from decades of clinical use of pharmaceutical somatropin and from observations of acromegaly (chronic endogenous GH hypersecretion). In rodent studies using supraphysiological rhGH doses (above 0.5 mg/kg/day in rats), reported findings include fluid retention and oedema (due to sodium and water retention mediated by renal tubular effects), hyperglycaemia and insulin resistance (due to GH antagonism of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue), and organomegaly, particularly of the kidneys, liver, and heart. ^[17] Carpal tunnel syndrome equivalents are not applicable in rodent models, but nerve compression pathology in transgenic GH-overexpressing mice is well documented.

In transgenic mice constitutively overexpressing human GH, reduced lifespan relative to wild-type controls has been reported, providing a counterintuitive longevity finding that is mechanistically linked to chronic IGF-1 elevation and oxidative stress. ^[17] This finding has been extensively discussed in the aging biology literature and is a key reason why GH-axis research for longevity endpoints requires careful dose and exposure design.

Receptor Desensitisation

Sustained continuous exposure to high-concentration rhGH downregulates GHR surface expression through receptor internalisation and reduced transcription of the GHR gene. In cell-based models, continuous exposure to 100 nM rhGH for 24 hours reduces surface GHR density by approximately 60 percent and JAK2-STAT5 signalling by approximately 50 percent. ^[8] This desensitisation is reversible over 12-24 hours after GH removal. Researchers conducting multi-day stimulation experiments should account for this adaptation in their signalling endpoint interpretations.

Immunogenicity Considerations in Animal Models

Recombinant proteins can elicit anti-drug antibody (ADA) responses in animal species used for chronic dosing studies. Rats administered heterologous (species-non-equivalent) rhGH for longer than 4 weeks develop detectable binding antibodies in approximately 20-40 percent of animals, which can neutralise GH activity and confound long-term results. The 191AA sequence has lower immunogenicity than the 192AA met-GH form. ^[3] For studies extending beyond 4 weeks, periodic measurement of circulating IGF-1 as a functional readout of GH activity is recommended to detect early antibody development.

How It Compares: HGH 191AA vs Related GH-Axis Compounds

Contextualising the Comparison

Direct-acting somatropin (HGH 191AA) occupies a unique position in this landscape because it engages the full GHR signalling cascade without requiring an endogenous GH-axis relay. Secretagogues (GHRP-6, ipamorelin, MK-677) stimulate the pituitary to release endogenous GH, meaning their effects are bounded by the somatotroph cell's secretory reserve and are subject to somatostatin feedback. In hypophysectomised animals or in in vitro cell models, secretagogues have no GH-axis effect without an endogenous pituitary, making direct somatropin the only option for GH-axis research in those models.

GHRH analogs (CJC-1295, sermorelin, tesamorelin) act upstream of somatotrophs and produce a more physiological, pulsatile GH pattern than direct subcutaneous bolus somatropin, but again require an intact pituitary. Tesamorelin is notable for being the only GHRH analog with FDA approval (for HIV-associated lipodystrophy), providing a high-quality clinical evidence base. ^[18] Researchers studying visceral fat reduction mechanisms may find the tesamorelin-vs-somatropin comparison useful for dissecting GHRH-receptor-specific from GHR-specific signalling.

IGF-1 (mecasermin) bypasses the GH receptor entirely, making it the correct choice when researchers want to isolate IGF-1R-specific signalling from direct GHR-mediated effects. The combination of rhGH plus IGF-1 blockade (using an IGF-1R antibody or IGF-1 binding protein excess) is a common experimental design for separating direct GH effects from indirect IGF-1-mediated effects in tissue-level studies.

Where to Buy

Apollo Peptide Sciences is the affiliated vendor for this product. Their HGH 191AA Somatropin 15IU listing provides the most up-to-date pricing, stock availability, and CoA download links. Before purchasing from any research-peptide supplier, review our independent supplier evaluation guide, which covers vendor criteria including third-party testing transparency, CoA completeness, shipping conditions, and laboratory accreditation.

Researchers sourcing multiple GH-axis compounds for comparative studies should review the related product listings below. Having complementary tools such as a GHRP, a GHRH analog, and direct somatropin enables clean experimental triangulation of where in the signalling cascade a phenotype of interest originates.

When evaluating any research-peptide vendor, the criteria that most reliably predict product quality are: (1) published HPLC-SEC data showing monomer content above 95 percent, (2) bioassay activity data reported as IU/mg against a referenced international standard, (3) endotoxin data from an accredited laboratory, and (4) mass spectrometry identity confirmation. See our supplier evaluation criteria for a scoring framework that can be applied to any vendor's CoA.

Open Research Questions

Despite the extensive literature on somatropin, several areas of active investigation remain relevant for researchers using this compound.

Isoform-specific biology of the 20 kDa variant: The 20 kDa GH isoform, absent from 191AA recombinant preparations, has been reported to have distinct biological activities, including different effects on glucose metabolism and potentially different receptor binding kinetics. Whether the predominant 22 kDa form fully recapitulates whole pituitary GH effects in in vivo models remains debated. Researchers studying GH effects in hypophysectomised animals should be aware that replacing only the 22 kDa form may not fully normalise all pituitary-dependent endpoints.

STAT5b vs STAT5a tissue specificity: While STAT5b is established as the dominant mediator of hepatic IGF-1 transcription, the relative roles of STAT5a and STAT5b in non-hepatic tissues (muscle, bone, brain) are less clearly defined. Some studies suggest STAT5a-mediated GH signalling in mammary tissue is required for lactation-associated metabolic adaptations, but the broader anabolic effects of STAT5a in muscle are understudied.

GH receptor negative regulators: SOCS2 (suppressor of cytokine signalling 2) is a feedback inhibitor of JAK2 signalling that is itself transcriptionally induced by GH-STAT5b activity. SOCS2 knockout mice show severe gigantism despite normal GH levels, indicating that SOCS2 provides a critical brake on GH signalling. The kinetics of SOCS2 induction and its dose-response relationship with GH concentration are not fully characterised, leaving important questions about the therapeutic window for maximal anabolic signal versus desensitisation.

Species differences in GHR structure and binding affinity: Human GH binds the human GHR with approximately 10-fold higher affinity than it binds the rodent GHR, due to differences in the receptor binding interface at Site 2. This means that dose-response studies in rodent models using human recombinant GH may underestimate tissue effects relative to species-matched GH at the same nominal concentration. This is a systematic limitation of using rhGH in rodent models that is rarely acknowledged in methods sections.

Pharmacological Context and Adaptation Biology

The GH-IGF-1 axis operates within a broader neuroendocrine regulatory framework that determines how exogenous rhGH administration interacts with endogenous hormonal homeostasis. GH secretion from the pituitary is driven by hypothalamic GHRH and inhibited by somatostatin, with ghrelin providing an additional stimulatory input from peripheral tissues. Exogenous rhGH administration suppresses endogenous GH secretion through dual negative feedback: directly at the pituitary (reducing somatotroph responsiveness to GHRH) and indirectly through elevated IGF-1 (which stimulates somatostatin release from the hypothalamus and reduces GHRH receptor expression on somatotrophs). ^[7] In long-term in vivo studies, this feedback means that total GH exposure (endogenous plus exogenous) is partially buffered, and the net increment in IGF-1 may be smaller than expected from the exogenous dose alone.

Tissue adaptation to chronic GH exposure involves not only GHR downregulation (described above) but also upregulation of IGF-1 signalling pathway components, including IRS-1, PI3K p85 subunit, and AKT in muscle tissue over 4-8 week treatment periods in rodents. This adaptive upregulation creates a time-dependent shift in the signalling phenotype from direct GHR-dominant (acute, 0-7 days) to IGF-1R-dominant (chronic, 4+ weeks), with important implications for which signalling endpoints are most informative at each study timepoint. Researchers designing time-course studies should plan tissue collection at multiple intervals to capture both phases.

The interaction between GH and sex steroids adds another layer of complexity. Oestrogen reduces hepatic GHR expression and increases GH pulse frequency but reduces amplitude, resulting in lower IGF-1 despite higher total GH exposure. Testosterone amplifies the IGF-1 response to GH. These interactions mean that sex-matched experimental groups and, in longer studies, gonadal steroid monitoring are important confound controls in GH-axis research. Most published rodent GH studies use male animals exclusively; caution is required when extrapolating to female models without additional validation.

The GH-cortisol interaction is relevant for stress-model experiments. Glucocorticoids suppress GHR expression at the transcriptional level and reduce STAT5b phosphorylation in response to GH, effectively inducing GH resistance in the liver. Animals exposed to chronic restraint or social defeat stress show significantly blunted IGF-1 responses to exogenous rhGH, which can confound body composition and muscle mass endpoints in any stress co-administration study. Measuring corticosterone (in rodents) as a covariate in GH-axis studies is recommended.

FAQ